| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 150, 1231-1244, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
T Luther, V Magdolen, S Albrecht, M Kasper, C Riemer, H Kessler, H Graeff, M Muller and M Schmitt
Institut fur Pathologie, Technische Universitat Dresden, Germany.
uPAR (CD87), the receptor for the urokinase-type plasminogen activator (uPA) facilitates tumor cell invasion and metastasis by focusing uPA proteolytic activity to the cell surface. As uPAR exists in various molecular forms, it is desirable to use well defined antibodies for analyses of uPAR antigen expression in human malignant tumors by immunological methods. Therefore, twelve monoclonal antibodies (MAbs) directed against uPAR were generated by using nonglycosylated, recombinant human uPAR (spanning amino acids 1 to 284), expressed in Escherichia coli, as the immunogen. The reaction pattern of these MAbs with the immunogen and a series of carboxyl-terminally truncated versions of uPAR demonstrated that at least six different epitopes of uPAR are recognized. All MAbs reacted under reducing conditions in immunoblot analyses with E. coli-expressed uPA and also with highly glycosylated, functionally intact, recombinant human uPAR expressed in Chinese hamster ovary (CHO) cells. Seven of the MAbs recognized CHO uPAR under nonreducing conditions as well. By flow cytofluorometric analyses, three of these MAbs were shown to bind to native human uPAR present on the cell surface of monocytoid U937 cells with MAb IIIF10 being the best. Saturation of uPAR with uPA on U937 cells completely blocked interaction of MAb IIIF10 with uPAR (mapped epitope, amino acids 52 to 60 of domain I of uPAR). In turn, preincubation of U937 cells with MAb IIIF10 efficiently reduced binding of uPA to uPAR, indicating that the epitope detected by MAb IIIF10 is located within or closely to the uPA-binding site of uPAR, and thus, this site may be a target to influence uPA/uPAR-mediated proteolysis in tumors. Binding of MAbs IID7 or IIIB11 (mapped epitope, amino acids 125 to 132 of domain II of uPAR) to uPAR is not affected when uPAR is occupied by uPA. As these MAbs reacted strongly with cellular uPAR antigen in formalin- fixed paraffin-embedded tumor sections, the domain-II-specific antibodies IID7 and IIIB11 may be useful for immunohistochemical studies of uPAR expression in tissue remodeling processes in tumor invasion. In conclusion, we have devised well defined and epitope- mapped MAbs to uPAR that are highly specific tools for detection and targeting of uPAR in tumor tissue.
This article has been cited by other articles:
 |
|
 |
|
  T. C. Hurd, S. Sait, S. Kohga, J. Winston, M. Martinick, R. Saxena, H. Lankes, G. Markus, S. Harvey, and J. F. Gibbs Plasminogen Activator System Localization in 60 Cases of Ductal Carcinoma In Situ Ann. Surg. Oncol., November 1, 2007; 14(11): 3117 - 3124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beaufort, D. Leduc, H. Eguchi, K. Mengele, D. Hellmann, T. Masegi, T. Kamimura, S. Yasuoka, F. Fend, M. Chignard, et al. The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1263 - L1272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rono, J. Romer, S. Liu, T. H. Bugge, S. H. Leppla, and P. E.G. Kristjansen Antitumor efficacy of a urokinase activation-dependent anthrax toxin Mol. Cancer Ther., January 1, 2006; 5(1): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nunomura, K. Nagano, C. Itagaki, M. Taoka, N. Okamura, Y. Yamauchi, S. Sugano, N. Takahashi, T. Izumi, and T. Isobe Cell Surface Labeling and Mass Spectrometry Reveal Diversity of Cell Surface Markers and Signaling Molecules Expressed in Undifferentiated Mouse Embryonic Stem Cells Mol. Cell. Proteomics, December 1, 2005; 4(12): 1968 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beaufort, D. Leduc, J.-C. Rousselle, V. Magdolen, T. Luther, A. Namane, M. Chignard, and D. Pidard Proteolytic Regulation of the Urokinase Receptor/CD87 on Monocytic Cells by Neutrophil Elastase and Cathepsin G J. Immunol., January 1, 2004; 172(1): 540 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. van der Pluijm, B. Sijmons, H. Vloedgraven, C. van der Bent, J.-W. Drijfhout, J. Verheijen, P. Quax, M. Karperien, S. Papapoulos, and C. Lowik Urokinase-Receptor/Integrin Complexes Are Functionally Involved in Adhesion and Progression of Human Breast Cancer in Vivo Am. J. Pathol., September 1, 2001; 159(3): 971 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Woodhead, T. J. Stonehouse, M. H. Binks, K. Speidel, D. A. Fox, A. Gaya, D. Hardie, A. J. Henniker, V. Horejsi, K. Sagawa, et al. Novel molecular mechanisms of dendritic cell-induced T cell activation Int. Immunol., July 1, 2000; 12(7): 1051 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gardsvoll, K. Dano, and M. Ploug Mapping Part of the Functional Epitope for Ligand Binding on the Receptor for Urokinase-type Plasminogen Activator by Site-directed Mutagenesis J. Biol. Chem., December 31, 1999; 274(53): 37995 - 38003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Harvey, S. N. J. Sait, Y. Xu, J. L. Bailey, R. M. Penetrante, and G. Markus Demonstration of Urokinase Expression in Cancer Cells of Colon Adenocarcinomas by Immunohistochemistry and in Situ Hybridization Am. J. Pathol., October 1, 1999; 155(4): 1115 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Suzuki, Y Hayashi, Y Wang, T Nakamura, Y Morita, K Kawasaki, K Ohta, N Aoyama, S R Kim, H Itoh, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms Gut, December 1, 1998; 43(6): 798 - 805. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
